Treatment Toxicities in Long-Term Survivors of Limited Small Cell Lung Cancer
作者:
FrytakS.,
ShawJ. N.,
LeeR. E.,
EaganR. T.,
ShawE. G.,
RichardsonR. L.,
CreaganE. T.,
ColesD. T.,
JettJ. R.,
期刊:
Cancer Investigation
(Taylor Available online 1988)
卷期:
Volume 6,
issue 6
页码: 669-676
ISSN:0735-7907
年代: 1988
DOI:10.3109/07357908809078033
出版商: Taylor&Francis
数据来源: Taylor
摘要:
AbstractA total of 211 patients with limited small cell lung cancer were assessed retrospectively for long-term toxicities, treatment-related deaths, and second primaries. All had received treatment with various combinations of doxorubicin, vincristine, cispla-tin, lomustine, cyclophosphamide, and etoposide with or without split-course thoracic radiotherapy (4,000 cGy/10 fractions) and/or split-course prophylactic cranial irradiation (3,600 cGy/10 fractions). Sixty-eight (32%) ofthe patients survived longer than 1.5 years and formed the basis of this study. Debilitating pulmonary, cardiac, and neurologic toxicity was noted in 12%, 14%, and 15%, respectively, of long-term survivors. These complications were the result of aggressive combined modality therapy. Certain drugs appeared to cause additive toxicity when combined with radiation. Three patients developed new primary tumors of squamous cell origin. Attention must be directed to defining the safest way to employ aggressive combined modality treatment for these patients.
点击下载:
PDF (635KB)
返 回